NasdaqGM - Nasdaq Real Time Price USD

Voyager Acquisition Corp. (VACHU)

10.50

+0.21

+(2.04%)

At close: May 7 at 4:00:00 PM EDT

VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program

Partnership Combines VERAXA's Proprietary ADC Technology with OmniAb's Antibody Discovery Technology for Novel Therapies Targeting Solid TumorsZURICH, SWITZERLAND, May 05, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ: VACH, "Voyager"), announced today a co-discovery alliance with OmniAb, Inc. (NASDAQ: OABI, “OmniAb”) for the development of a novel bispecif

GlobeNewswire 8 days ago

VACH

VACHU
+2.04%

VACHW
Veraxa to go public in $1.6bn SPAC deal with Voyager

Veraxa Biotech will gain access to $253m in cash from Voyager to advance its cancer drug pipeline.

Pharmaceutical Technology 20 days ago

GLDAF

VACHW
VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies

VERAXA’s Novel BiTAC Platform has the Potential to Deliver Multiple Next-Generation Solid Tumor Cancer Therapies, Including Novel Antibody-Drug Conjugate ("ADC") and Bispecific T-cell Engager ("TCE") Candidates, with Strong and Differentiated Clinical ProfilesCompany Pursuing Multiple Strategic Partnerships and Licensing Opportunities in 2025 and 2026Transaction Values VERAXA at a Pre-money Equity Value of $1.3 BillionActively Working with Existing and New VERAXA Investors to Raise a Crossover F

GlobeNewswire 21 days ago

VACH

VACHU
+2.04%

VACHW
Voyager Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing on or about September 30, 2024

BROOKLYN, N.Y., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Voyager Acquisition Corp. (Nasdaq: VACHU) (the “Company”) announced that holders of the units sold in the Company’s initial public offering of 25,300,000 units, which includes 3,300,000 units issued pursuant to the exercise by the underwriters of their overallotment option, completed on August 12, 2024 (the “Offering”) may elect to separately trade the Class A ordinary shares and warrants included in the units commencing on or about September 30

GlobeNewswire 7 months ago

VACHU
+2.04%
Voyager Acquisition Corp. Announces Closing of $253,000,000 Initial Public Offering

BROOKLYN, N.Y., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Voyager Acquisition Corp. (Nasdaq: VACHU) (the “Company”) today announced that it closed its initial public offering of 25,300,000 units at $10.00 per unit, including the issuance of 3,300,000 units as result of the underwriters’ exercise of its over-allotment option in full. The gross proceeds from the offering were $253 million before deducting underwriting discounts and estimated offering expenses. The units began trading on the Nasdaq Global

GlobeNewswire 8 months ago

VACHU
+2.04%
Voyager Acquisition Corp. Announces Pricing of $220,000,000 Initial Public Offering

BROOKLYN, N.Y., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Voyager Acquisition Corp. (Nasdaq: VACHU) (the “Company”) announced today the pricing of its initial public offering of 22,000,000 units at $10.00 per unit. The units are expected to be listed on the Nasdaq Global Market (“Nasdaq”) and trade under the ticker symbol “VACHU” beginning August 9, 2024. Each unit consists of one Class A ordinary share and one-half of one redeemable warrant. Once the securities comprising the units begin separate tradi

GlobeNewswire 8 months ago

VACHU
+2.04%

Performance Overview

Return	VACHU	S&P 500 (^GSPC)
YTD	+3.75%	+0.08%
1-Year	+5.00%	+12.74%
3-Year	+5.00%	+46.29%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Voyager Acquisition Corp. (VACHU)

VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program

Veraxa to go public in $1.6bn SPAC deal with Voyager

VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies

Voyager Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing on or about September 30, 2024

Voyager Acquisition Corp. Announces Closing of $253,000,000 Initial Public Offering

Voyager Acquisition Corp. Announces Pricing of $220,000,000 Initial Public Offering

Performance Overview